Needle-free mode of T-20 dosing looks highly satisfactory for patients

A needle-free method of adinistering the anti-HIV drug T-20 (enfuvirtide, Fuzeon) is tolerable and acceptable to patients in the long term, according to a study presented to the Sixteenth International AIDS Conference in Toronto last week. The investigators found that 75% of patients found the Biojector B2000 preferable to the current needle and syringe method of T-20 administration.

Read More >>